{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:18:03Z","timestamp":1768004283753,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"FCT-Funda\u00e7\u00e3o para a ci\u00eancia e Tecnologia","award":["EXPL\/BIM-ONC\/0556\/2012"],"award-info":[{"award-number":["EXPL\/BIM-ONC\/0556\/2012"]}]},{"name":"FCT","award":["SFRH\/BD\/71293\/2010"],"award-info":[{"award-number":["SFRH\/BD\/71293\/2010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12943-017-0604-0","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T05:24:13Z","timestamp":1485840253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b\/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors"],"prefix":"10.1186","volume":"16","author":[{"given":"Jorge","family":"Torres-Ferreira","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o","family":"Ramalho-Carvalho","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Gomez","sequence":"additional","affiliation":[]},{"given":"Francisco Duarte","family":"Menezes","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Freitas","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Antunes","sequence":"additional","affiliation":[]},{"given":"Maria Jos\u00e9","family":"Bento","sequence":"additional","affiliation":[]},{"given":"Manel","family":"Esteller","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"key":"604_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5\u201329.","journal-title":"CA Cancer J Clin"},{"key":"604_CR2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u2013386.","journal-title":"Int J Cancer"},{"key":"604_CR3","doi-asserted-by":"crossref","unstructured":"Hammerich K, Ayala GE, TM W. Anatomy of the prostate gland and surgical pathology of prostate cancer. In: Prostate Cancer Edited by Hedvig Hricak and Peter T. Scardino. Cambridge: Cambridge University Press; 2009. p. 1\u201314.","DOI":"10.1017\/CBO9780511551994.003"},{"key":"604_CR4","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1586\/14737140.2014.952288","volume":"14","author":"P Costa-Pinheiro","year":"2014","unstructured":"Costa-Pinheiro P, Patel HR, Henrique R, Jeronimo C. Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer. Expert Rev Anticancer Ther. 2014;14:1349\u201358.","journal-title":"Expert Rev Anticancer Ther"},{"key":"604_CR5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejca.2008.12.008","volume":"45","author":"MJ Duffy","year":"2009","unstructured":"Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, Sweep FC, Brunner N, Foekens JA, Schmitt M, Group EP. Methylated genes as new cancer biomarkers. Eur J Cancer. 2009;45:335\u201346.","journal-title":"Eur J Cancer"},{"key":"604_CR6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.canlet.2011.12.026","volume":"342","author":"C Jeronimo","year":"2014","unstructured":"Jeronimo C, Henrique R. Epigenetic biomarkers in urological tumors: A systematic review. Cancer Lett. 2014;342:264\u201374.","journal-title":"Cancer Lett"},{"key":"604_CR7","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/jnci\/djg082","volume":"95","author":"SV Harden","year":"2003","unstructured":"Harden SV, Sanderson H, Goodman SN, Partin AA, Walsh PC, Epstein JI, Sidransky D. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst. 2003;95:1634\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"604_CR8","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.juro.2011.06.052","volume":"186","author":"J Baden","year":"2011","unstructured":"Baden J, Adams S, Astacio T, Jones J, Markiewicz J, Painter J, Trust C, Wang Y, Green G. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0\u00a0ng\/ml using an investigational prostate cancer methylation assay. J Urol. 2011;186:2101\u20136.","journal-title":"J Urol"},{"key":"604_CR9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3892\/or.2013.2913","volume":"31","author":"QW Chen","year":"2014","unstructured":"Chen QW, Zhu XY, Li YY, Meng ZQ. Epigenetic regulation and cancer (review). Oncol Rep. 2014;31:523\u201332.","journal-title":"Oncol Rep"},{"key":"604_CR10","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/onc.2011.354","volume":"31","author":"P Lopez-Serra","year":"2012","unstructured":"Lopez-Serra P, Esteller M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene. 2012;31:1609\u201322.","journal-title":"Oncogene"},{"key":"604_CR11","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-07-1042","volume":"13","author":"R Henrique","year":"2007","unstructured":"Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, Pinto M, Oliveira J, Teixeira MR, Sidransky D, Jeronimo C. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res. 2007;13:6122\u20139.","journal-title":"Clin Cancer Res"},{"key":"604_CR12","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/jnci\/djp122","volume":"101","author":"MR Cooperberg","year":"2009","unstructured":"Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009;101:878\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"604_CR13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.canlet.2012.02.011","volume":"342","author":"K Chiam","year":"2014","unstructured":"Chiam K, Ricciardelli C, Bianco-Miotto T. Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett. 2014;342:248\u201356.","journal-title":"Cancer Lett"},{"key":"604_CR14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","volume":"157","author":"VA Moyer","year":"2012","unstructured":"Moyer VA, Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120\u201334.","journal-title":"Ann Intern Med"},{"key":"604_CR15","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1373\/clinchem.2013.205450","volume":"59","author":"Z Lichner","year":"2013","unstructured":"Lichner Z, Fendler A, Saleh C, Nasser AN, Boles D, Al-Haddad S, Kupchak P, Dharsee M, Nuin PS, Evans KR, et al. MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem. 2013;59:1595\u20131603.","journal-title":"Clin Chem"},{"key":"604_CR16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.molonc.2012.07.007","volume":"6","author":"H Suzuki","year":"2012","unstructured":"Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012;6:567\u201378.","journal-title":"Mol Oncol"},{"key":"604_CR17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13148-015-0097-x","volume":"7","author":"C Gallego-Fabrega","year":"2015","unstructured":"Gallego-Fabrega C, Carrera C, Mui\u00f1o E, Montaner J, Krupinski J, Fernandez-Cadenas I. DNA methylation levels are highly correlated between pooled samples and averaged values when analysed using the Infinium HumanMethylation450 BeadChip array. Clin Epigenetics. 2015;7:48.","journal-title":"Clin Epigenetics"},{"key":"604_CR18","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/onc.2014.111","volume":"34","author":"F Valdes-Mora","year":"2015","unstructured":"Valdes-Mora F, Clark SJ. Prostate cancer epigenetic biomarkers: next-generation technologies. Oncogene. 2015;34:1609\u201318.","journal-title":"Oncogene"},{"key":"604_CR19","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1111\/jcmm.12394","volume":"18","author":"M Almeida","year":"2014","unstructured":"Almeida M, Costa VL, Costa NR, Ramalho-Carvalho J, Baptista T, Ribeiro FR, Paulo P, Teixeira MR, Oliveira J, Lothe RA, et al. Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential. J Cell Mol Med. 2014;18:2287\u201397.","journal-title":"J Cell Mol Med"},{"key":"604_CR20","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-13-2642","volume":"20","author":"H Kristensen","year":"2014","unstructured":"Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, et al. Hypermethylation of the GABRE\u2009~\u2009miR-452\u2009~\u2009miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res. 2014;20:2169\u201381.","journal-title":"Clin Cancer Res"},{"key":"604_CR21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/sj.bjc.6602311","volume":"92","author":"R Thuret","year":"2005","unstructured":"Thuret R, Chantrel-Groussard K, Azzouzi AR, Villette JM, Guimard S, Teillac P, Berthon P, Houlgatte A, Latil A, Cussenot O. Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer. Br J Cancer. 2005;92:236\u201340.","journal-title":"Br J Cancer"},{"key":"604_CR22","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cam4.486","volume":"4","author":"KM Kaukoniemi","year":"2015","unstructured":"Kaukoniemi KM, Rauhala HE, Scaravilli M, Latonen L, Annala M, Vessella RL, Nykter M, Tammela TL, Visakorpi T. Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. Cancer Med. 2015;4:1417\u201325.","journal-title":"Cancer Med"},{"key":"604_CR23","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/ijc.25162","volume":"127","author":"HE Rauhala","year":"2010","unstructured":"Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, Oja H, Visakorpi T. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer. 2010;127:1363\u201372.","journal-title":"Int J Cancer"},{"key":"604_CR24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.juro.2012.04.143","volume":"189","author":"M Truong","year":"2013","unstructured":"Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis. J Urol. 2013;189:422\u20139.","journal-title":"J Urol"},{"key":"604_CR25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1373\/clinchem.2005.062919","volume":"52","author":"H Muller","year":"2006","unstructured":"Muller H, Brenner H. Urine markers as possible tools for prostate cancer screening: review of performance characteristics and practicality. Clin Chem. 2006;52:562\u201373.","journal-title":"Clin Chem"},{"key":"604_CR26","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2008.01.013","volume":"179","author":"H Nakanishi","year":"2008","unstructured":"Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179:1804\u20139. discussion 1809\u20131810.","journal-title":"J Urol"},{"key":"604_CR27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrurol.2009.261","volume":"7","author":"G Ploussard","year":"2010","unstructured":"Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol. 2010;7:101\u20139.","journal-title":"Nat Rev Urol"},{"key":"604_CR28","doi-asserted-by":"crossref","first-page":"127rv123.brs","DOI":"10.1126\/scitranslmed.3003180","volume":"4","author":"JR Prensner","year":"2012","unstructured":"Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 2012;4:127rv123.brs.","journal-title":"Sci Transl Med"},{"key":"604_CR29","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.juro.2013.12.005","volume":"191","author":"KK Chevli","year":"2014","unstructured":"Chevli KK, Duff M, Walter P, Yu C, Capuder B, Elshafei A, Malczewski S, Kattan MW, Jones JS. Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy. J Urol. 2014;191:1743\u20138.","journal-title":"J Urol"},{"key":"604_CR30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/pros.22942","volume":"75","author":"MJ Roberts","year":"2015","unstructured":"Roberts MJ, Chow CW, Schirra HJ, Richards R, Buck M, Selth LA, Doi SA, Samaratunga H, Perry-Keene J, Payton D, et al. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer. Prostate. 2015;75:539\u201349.","journal-title":"Prostate"},{"key":"604_CR31","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/bjc.2011.595","volume":"106","author":"RJ Bryant","year":"2012","unstructured":"Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106:768\u201374.","journal-title":"Br J Cancer"},{"key":"604_CR32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/bjc.2016.233","volume":"115","author":"K Stuopelyte","year":"2016","unstructured":"Stuopelyte K, Daniunaite K, Bakavicius A, Lazutka JR, Jankevicius F, Jarmalaite S. The utility of urine-circulating miRNAs for detection of prostate cancer. Br J Cancer. 2016;115:707\u201315.","journal-title":"Br J Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-017-0604-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T03:37:00Z","timestamp":1568777820000},"score":1,"resource":{"primary":{"URL":"http:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-017-0604-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,31]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1186\/s12943-017-0604-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,31]]},"article-number":"26"}}